Other languages Fulgent Genetics, Inc.

Equities

FLGT

US3596641098

Market Closed - Nasdaq Other stock markets 16:00:00 2024-04-26 EDT			5-day change	1st Jan Change
20.1 ^USD	+0.35%		-1.28%	-30.47%

03-06	Piper Sandler Adjusts Price Target on Fulgent Genetics to $25 From $28, Maintains Neutral Rating	MT
02-29	UBS Adjusts Fulgent Genetics Price Target to $25 From $35, Maintains Neutral Rating	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Fulgent Genetics, Inc. Provides Earnings Guidance for the Year 2024	02-28
Fulgent Genetics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-28
Cooper Unit, Fulgent Genetic to Offer Newborn Genetic Screening Panels	02-09
Cord Blood Registry by CooperSurgical, Inc. and Fulgent Genetics, Inc. Launch Innovative Genetic Testing	02-09
Fulgent Genetics, Inc. Announces Two Poster Presentations At SITC 2023 Annual Meeting	11-03
Fulgent Genetics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-03
Fulgent Genetics, Inc. Reiterates Earnings Guidance for the Full Year 2023	11-03
Insider Sell: Fulgent Genetics	23-08-30
Sector Update: Health Care Stocks Steady Premarket Friday	23-08-04
Fulgent Genetics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-04
Fulgent Genetics, Inc. Provides Earnings Guidance for the Third Quarter of 2023 and Full Year 2023	23-08-04
Fulgent Genetics, Inc. Announces Data from a Phase 1/1b Clinical Study of FID-007 in Treating Various Solid Tancers	23-06-05
Fulgent Genetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-05
Fulgent Genetics, Inc. Provides Earnings Guidance for the Second Quarter of 2023 and Full Year 2023	23-05-05
Fulgent Genetics to Use Mission Bio's Single-Cell Sequencing Platform	23-04-11
Fulgent Genetics Swings to Loss in Q4 As Revenue Plunges; Issues Guidance	23-02-28
Fulgent Genetics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-28
Fulgent Genetics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-28
Fulgent Genetics, Inc. Provides Earning Guidance for First Quarter of 2023 and Full Year 2023	23-02-28
Fulgent Genetics Launches New Beacon787 Expanded Carrier Screening Panel	23-02-28

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Fulgent Genetics, Inc.

Equities

FLGT

US3596641098

Other languages

Filters